Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourBullish
15 minLeaning Bearish
5 minLeaning Bullish
Daily trend turns down below $91.03
Key levels
Resistance$95.26
Resistance$91.03
Support$85.80
Support$81.69
Latest news & SEC filings
ProductCVS Pharmacy launches Caliber Artist Series journals
AnalystWells Fargo keeps Overweight on CVS Health, cuts target to $112
NewsCVS Health earns seven honors for artificial intelligence work.
All CVS news →CVS Health is a health solutions company with four segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Through Aetna, it offers medical, dental, behavioral health, Medicare Advantage, Medicare Supplement, Medicare Part D, and Medicaid coverage to employer groups, government programs, and individuals. Its pharmacy business includes a pharmacy benefits manager and retail pharmacies, and it operates walk-in and primary care clinics. It serves customers across the United States and in some other countries.
Based on the company's 10-K filed Feb 10, 2026.
NYSE · Healthcare
SEPT Low Target
$94.00
SEPT Mid Target
$110.50
SEPT High Target
$125.00
Analyst Consensus
$110.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CVS.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$124.61
24
Moat Score
NONE
5/9
Piotroski Score
2.3
Altman Z-Score
Insider Signal
SELLING
1 buys / 7 sells (90d)
Congress Signal
BUYING
8 buys / 12 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Shah Prem S | officer | Buy | 23,855 | $2.0M | Nov 6, 2026 |
| Clark James David | officer | Sale | 454 | $41K | Jun 26, 2026 |
| Newman Brian | officer | Sale | 2,478 | $225K | May 31, 2026 |
| Compton-Phillips Amy | officer | Sale | 7,618 | $693K | May 31, 2026 |
| ROBBINS LARRY | director | Sale | 370,462 | $34.6M | May 21, 2026 |
| AGUIRRE FERNANDO | director | Sale | 1,563 | $146K | May 21, 2026 |
| ROBBINS LARRY | director | Sale | 797,628 | $74.6M | May 20, 2026 |
| ROBBINS LARRY | director | Sale | 152,691 | $14.5M | May 20, 2026 |
| ROBBINS LARRY | director | Sale | 66,881 | $6.4M | May 20, 2026 |
| ROBBINS LARRY | director | Sale | 800 | $77K | May 20, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
7.8%
3yr Revenue CAGR
7.6%
EPS Growth YoY
-62.02%
FCF Growth YoY
23.4%
Revenue Trend
STABLE
SEPT Investing tracks real-time dark pool institutional trades for CVS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:34:06 | $89.79 | 1,500 | $$135K | SELL |
| 20:33:32 | $89.78 | 2,200 | $$198K | MIDPOINT |
| 20:31:43 | $89.76 | 9,474 | $$850K | SELL |
| 20:28:58 | $89.67 | 2,880 | $$258K | BUY |
| 20:27:38 | $89.67 | 1,268 | $$114K | BUY |
5 dark pool trades shown · $$1.6M preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for CVS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $85 | May 21 | 190 | $$1105 | 1 | SWEEP |
| CALL | $85 | May 21 | 190 | $$11.1K | 10 | SWEEP |
| CALL | $85 | May 21 | 190 | $$5525 | 5 | SWEEP |
| CALL | $85 | May 21 | 190 | $$5525 | 5 | SWEEP |
| CALL | $85 | May 21 | 190 | $$1105 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for CVS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup — $CVS (CVS HEALTH Corp) Price: $79.96 | Zone: $77.33 — $91.89 Conviction: HIGH | Analyst upside: +40% Near support (18% of range, within one daily ATR) — reversal watch. Strong positive ...
Zone Setup -- $CVS (CVS HEALTH Corp) Price: $106.87 | Zone: $105.68 to $108.67 Conviction: HIGH | Analyst upside: +2.4% Near resistance (40% of range) — breakout watch. Strong positive news (3+ vs 1...
Join 3,500+ traders discussing CVS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for CVS HEALTH Corp (CVS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CVS HEALTH Corp (CVS) is at $89.79, up 0.30% (+$0.27) at the Nov 12, 2026 close.
Latest CVS news — Nov 12, 2026: CVS Pharmacy launches Caliber Artist Series journals · Nov 12, 2026: Wells Fargo keeps Overweight on CVS Health, cuts target to $112
CVS Health reported Q3 2026 results that included a $193 million Omnicare guarantee charge, and the stock fell 6.26% to close at $79.96 on heavy volume of 33.4 million shares. Despite the selloff, the company lifted its full-year outlook and confirmed plans to split into two separate public companies, with the Omnicare divestiture expected in late 2026.
The average analyst price target for CVS is $110.50, ranging from $94 to $125, based on 16 analysts. Latest: Wells Fargo maintains on Nov 12, 2026.
Analyst ratings for CVS: 0 Buy, 29 Hold, 0 Sell — consensus Hold.
CVS last reported on Nov 4, 2026: EPS $2.09 vs $1.65 expected — a beat of 26.7%.
CVS trades at a P/E of 10.4 vs a Healthcare average of 17.7.
Yes. CVS's dividend yield is 3.38%.
CVS HEALTH Corp reported $57.2B of debt and $11.7B of cash (Sep 30, 2026).
Support: $85.80, $81.69, $77.33. Resistance: $91.03, $95.26, $98.50.
Insider activity: SELLING, 1 buys and 7 sells in the last 90 days.
Nov 12, 2026: CVS Pharmacy launches Caliber Artist Series journals · Nov 12, 2026: Wells Fargo keeps Overweight on CVS Health, cuts target to $112 · Nov 11, 2026: CVS Health earns seven honors for artificial intelligence work.